[{"bbox": [91, 99, 368, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [91, 166, 1558, 204], "category": "Table", "text": "<table><tr><td>P/E ratio based on the Weighted Average EPS, as restated.</td><td>●</td><td>●</td></tr></table>"}, {"bbox": [89, 206, 1558, 270], "category": "Text", "text": "There are no listed companies in India that are engaged in a business similar to that of our company accordingly it is not possible to provide an industry comparison in relation to our company."}, {"bbox": [91, 301, 159, 329], "category": "Section-header", "text": "**Note:**"}, {"bbox": [140, 333, 1017, 364], "category": "List-item", "text": "i) The P/E ratio has been computed by dividing Market Price with EPS."}, {"bbox": [116, 396, 525, 428], "category": "Section-header", "text": "### 3. Return on Net worth (RoNW)"}, {"bbox": [91, 456, 1558, 627], "category": "Table", "text": "<table><thead><tr><td>Sr. No</td><td>Period</td><td>RONW (%)</td><td>Weights</td></tr></thead><tbody><tr><td>1</td><td>Financial Year ending March 31, 2025</td><td>23.74%</td><td>3</td></tr><tr><td>2</td><td>Financial Year ending March 31, 2024</td><td>21.29%</td><td>2</td></tr><tr><td>3</td><td>Financial Year ending March 31, 2023</td><td>25.20%</td><td>1</td></tr><tr><td colspan=\"2\">Weighted Average</td><td>23.17%</td><td></td></tr></tbody></table>"}, {"bbox": [91, 629, 273, 659], "category": "Text", "text": "*not annualized"}, {"bbox": [91, 694, 159, 721], "category": "Section-header", "text": "**Note:**"}, {"bbox": [120, 725, 1218, 756], "category": "List-item", "text": "i. The figures disclosed above are based on the Restated Financial Statements of the Company."}, {"bbox": [120, 758, 1558, 820], "category": "List-item", "text": "ii. The RoNW has been computed by dividing restated net profit after tax (excluding exceptional items) with restated Net worth as at the end of the year/period."}, {"bbox": [120, 822, 1558, 885], "category": "List-item", "text": "iii. Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights."}, {"bbox": [116, 915, 652, 948], "category": "Section-header", "text": "### 4. Net Asset Value (NAV) per Equity Share:"}, {"bbox": [91, 976, 1558, 1310], "category": "Table", "text": "<table><thead><tr><td>Sr. No.</td><td>NAV per Equity Share</td><td>Outstanding at the end of the year (Amt. in Rs.)</td></tr></thead><tbody><tr><td>1</td><td>As at March 31, 2023</td><td>80.87</td></tr><tr><td>2</td><td>As at March 31, 2024</td><td>102.74</td></tr><tr><td>3</td><td>As at March 31, 2025</td><td>120.60</td></tr><tr><td>4</td><td>NAV per Equity Share after the Issue</td><td></td></tr><tr><td></td><td>(i) At Floor Price</td><td>●</td></tr><tr><td></td><td>(ii) At Cap Price</td><td>●</td></tr><tr><td>5</td><td>Issue Price</td><td>●</td></tr></tbody></table>"}, {"bbox": [91, 1312, 1502, 1345], "category": "Text", "text": "*The above NAV has been calculated based on weighted number of shares outstanding at the end of the respective year/period."}, {"bbox": [91, 1377, 168, 1405], "category": "Section-header", "text": "**Notes:**"}, {"bbox": [116, 1409, 1196, 1439], "category": "List-item", "text": "i. The figures disclosed above are based on the Restated Financial Statements of the Company."}, {"bbox": [116, 1440, 1558, 1503], "category": "List-item", "text": "ii. NAV per share = Restated Net worth at the end of the year/period divided by weighted average number of equity shares outstanding at the end of the year/period"}, {"bbox": [116, 1505, 1558, 1568], "category": "List-item", "text": "iii. Net worth is computed as the sum of the aggregate of paid-up equity share capital, all reserves created out of the profits, securities premium account received in respect of equity shares and debit or credit balance of profit and loss account."}, {"bbox": [116, 1568, 1512, 1601], "category": "List-item", "text": "iv. Issue Price per Equity Share will be determined by our Company in consultation with the Book Running Lead Managers."}, {"bbox": [116, 1631, 819, 1664], "category": "Section-header", "text": "### 5. Comparison of Accounting Ratios with Industry Peers:"}, {"bbox": [91, 1696, 1558, 1760], "category": "Text", "text": "There are no listed companies in India that are engaged in the business line similar to that of our company, thus it is not possible to provide an industry comparison in relation to our company."}, {"bbox": [1389, 1760, 1558, 1789], "category": "Text", "text": "(Rs. In Lakhs)"}, {"bbox": [91, 1789, 1558, 1922], "category": "Table", "text": "<table><thead><tr><th rowspan=\"2\">Name of Company</th><th rowspan=\"2\">Current Market Price (₹)</th><th rowspan=\"2\">Face Value</th><th colspan=\"2\">EPS</th><th rowspan=\"2\">PE</th><th rowspan=\"2\">RoNW (%)</th><th rowspan=\"2\">Book Value (₹)</th><th rowspan=\"2\">Revenue from Operations</th></tr><tr><th>Basic</th><th>Diluted</th></tr></thead><tbody><tr><td>Q-line Biotech Limited</td><td>●</td><td>10</td><td>28.63</td><td>28.63</td><td>●</td><td>23.74%</td><td>120.60</td><td>31,378.04</td></tr></tbody></table>"}, {"bbox": [91, 1956, 168, 1983], "category": "Section-header", "text": "**Notes:**"}, {"bbox": [116, 1988, 1558, 2048], "category": "List-item", "text": "(i) The EPS, NAV, RoNW and total Income of our Company are taken as per Consolidated Restated Financial Statement for the Year March 31, 2025."}, {"bbox": [116, 2050, 1558, 2112], "category": "List-item", "text": "(ii) NAV per share is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2025."}, {"bbox": [116, 2114, 1077, 2147], "category": "List-item", "text": "(iii) RoNW has been computed as net profit after tax divided by closing net worth."}]